Form 4 for IBRX ImmunityBio, Inc.

Accepted 2025-01-03 00:00:00 ET · period of report 2024-12-31 · accession 0001326110-25-000004 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2025-01-03	2024-12-31	IBRX	Adcock Richard	CEO, Pres, Dir	M - OptEx	$0.00	+34.5K	277.6K	+14%	$0
D	2025-01-03	2024-12-31	IBRX	Adcock Richard	CEO, Pres, Dir	F - Tax	$2.56	-17.5K	260.1K	-6%	-$44.7K
D	2025-01-03	2024-12-31	IBRX	Adcock Richard	CEO, Pres, Dir	M - OptEx	$0.00	-34.5K	86.2K	-29%	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2024-12-31	M	A	34,483	$0.00	277,621	D	—	—
2	Common	Common Stock	2024-12-31	F	D	17,475	$2.56	260,146	D	—	—
3	Derivative	Restricted Stock Units	2024-12-31	M	D	34,483	$0.00	86,214	D	— · — to —	34,483 Common Stock	(F1) Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock. (F2) Five percent (5%) of the 172,420 RSUs (rounded down to the nearest whole share) vested on September 9, 2021; five percent (5%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2022; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2023; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2024; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2025; and the remaining RSUs will vest on December 31, 2026.